1-5 of 5
Michael J. Mauro
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Lifelong TKI therapy: how to manage cardiovascular and other risks

Free
Michael J. Mauro
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2021) 2021 (1): 113–121.
https://doi.org/10.1182/hematology.2021000239
Published: 2021
Journal Articles

Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy

Free
Mary C. Barber, Michael J. Mauro, Javid Moslehi
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 110–114.
https://doi.org/10.1182/asheducation-2017.1.110
Published: 2017
Journal Articles

Prognostic significance of early molecular response in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors

Free
David T. Yeung, Michael J. Mauro
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 240–243.
https://doi.org/10.1182/asheducation-2014.1.240
Published: 2014
Journal Articles

Goals for chronic myeloid leukemia TK inhibitor treatment: how little disease is too much?

Free
Michael J. Mauro
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 234–239.
https://doi.org/10.1182/asheducation-2014.1.234
Published: 2014
Journal Articles

Defining and Managing Imatinib Resistance

Free
Michael J. Mauro
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2006) 2006 (1): 219–225.
https://doi.org/10.1182/asheducation-2006.1.219
Published: 2006